– To investigate the pattern of use of different treatments (immunosuppressants, anti-
fibrotics or their combination) in patients with MPO-associated ILD
– To investigate the effectiveness of immunosuppressants (+/- anti-fibrotic agents) vs
anti-fibrotic agents in patients with MPO-associated ILD.
– To assess the rate of acute exacerbations following remission during treatment with
immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents;
– To assess the occurrence of AAV during treatment with immunosuppressants (+/-
anti-fibrotic agents) vs anti-fibrotic agents;
– To assess potential differences in term of prognosis (hospitalization, death) in
patients receiving immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic
agents;
– To assess the safety of the treatment with immunosuppressants (+/- anti-fibrotic
agents) vs anti-fibrotic agents